Home › Trials › NCT05412927

Evaluation of the AngelMed Guardian® System for patients with Acute Coronary Syndrome

AngelMed Guardian® System PMA Post Approval Study

Observational Angel Medical Systems · NCT05412927

This study is testing how well the AngelMed Guardian® System works for people who have had acute coronary syndrome and if healthcare providers are properly trained to use it.

Quick facts

Study typeObservational
Enrollment500 (estimated)
Ages21 Years and up
SexAll
SponsorAngel Medical Systems Industry-sponsored
Locations18 sites (Glendale, Arizona and 17 other locations)
Trial IDNCT05412927 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the diagnostic accuracy and compliance of the AngelMed Guardian® System in patients who have experienced acute coronary syndrome (ACS). A minimum of 500 patients will be enrolled after receiving the device, and their experiences will be monitored through standard care protocols, including regular follow-ups. The study will evaluate the performance of the device in detecting ACS events and the training adequacy for healthcare providers involved in patient care. The goal is to collect and adjudicate 314 ACS events to analyze the device's predictive value.

Who should consider this trial

Good fit: Ideal candidates include adults aged 21 and older with a history of high-risk acute coronary syndrome and specific comorbid conditions.

Not a fit: Patients who do not have a history of acute coronary syndrome or those living far from emergency medical services may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the early detection of recurrent ACS events, potentially improving patient outcomes.

How similar studies have performed: Previous studies have shown promise in using similar monitoring devices for ACS, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* 1\. Subject has at least one of the following conditions:

  1. Diabetes (Type I or Type II)
  2. Compromised renal function (Cr \> 1.2 mg/dl or creatinine clearance less than 50)
  3. TIMI Risk Score of at least 3

     2\. Previously diagnosed with a high-risk acute coronary syndrome (e.g., Unstable Angina, STEMI or NSTEMI) or has undergone or is scheduled for CABG within 6 months of implantation.

     3\. Has already undergone coronary angiography and revascularization, unless the physician determines it is appropriate to implant before or during the planned procedure.

     4\. Lives in a geographic area in close proximity (within approximately 60 minutes by EMS) to any hospital that can treat AMI.

     5\. Subjects (men or women) at least 21 years of age. Women of childbearing age must have a negative pregnancy test or confirmation of one of the following:

  <!-- -->

  1. Post-menopause or amenorrhoeic during the past year
  2. Surgical sterilization
  3. Use of effective contraceptive method

Exclusion Criteria:

* 1\. In the investigator's opinion, subject lacks ability to respond appropriately to alarms, e.g., illiteracy, poor memory or cognitive function, dementia or other condition affecting memory function, etc.

  2\. There is known compromised tissue at the site of lead implantation in the apex of the right ventricle, e.g., prior infarct affecting the RV apex location.

  3\. A permanent pacemaker or ICD is already in place or the subject is indicated for ICD or pacemaker implantation based on the guidelines published by the American College of Cardiology as Class I and IIa recommendations. Class IIb recommendations are at the investigator's discretion.

  4\. Subject cannot feel the IMD vibration when placed on top of the skin on the left pectoral side of the chest.

  5\. Subject has recurrent or persistent atrial fibrillation. 6. Subject has recurrent or persistent non-sinus cardiac rhythm, second or third degree atrioventricular blocks, QRS duration greater than 120 ms, Benign Early Repolarization (BER), Brugada Syndrome (LLB, BBB, RBB) or Rate Induced BBB.

  7\. Subject has left ventricular hypertrophy evidenced by EKG criteria. 8. Subject has any condition preventing the subcutaneous implantation of the Guardian® System in a left pectoral pouch, such as: superior vena cava thrombosis, subcutaneous tissue deemed inappropriate for the procedure or prior central venous access via portacath, Hickman, Groshong, or similar placed in a left pectoral location or left side PICC line.

  9\. Subject has extremely heavy alcohol consumption (participates in binge drinking that leads to alcohol intoxication) or has history of alcohol or illicit drug abuse within past 5 years.

  10\. There is evidence of unresolved infection (fever \> 38o C and/or leukocytosis \> 15,000).

  11\. Subject has history of bleeding disorders or severe coagulopathy (platelets \< 100,000 plts/ml; APTT or PT \> 1.3 x reference range).

  12\. Subject has had a hemorrhagic stroke or transient ischemic attack (TIA) in the past 6 months.

  13\. Subject has a potentially fatal disease, such as cancer or refractory congestive heart failure, associated with limitation of life expectancy, which may lead to inadequate compliance to the protocol or confusing data interpretation.

  14\. Subject has clinical conditions such as heart diseases, difficult-to-control blood pressure, difficult-to-control insulin-dependent diabetes or serious prior infections attributed to the diabetes, or others that, at the investigator's discretion, could seriously affect the subject's current clinical condition during study procedures.

  15\. Subject has previously been implanted with an AngelMed Guardian® System, current participation or previous participation in another drug or device study in the past 30 days that conflicts with this study as determined by the study sponsor.

  16\. Subject has experienced gastro-intestinal hemorrhage in the past 6 months. 17. Subject has any situation in which the use of aspirin is contraindicated for at least 6 months.

  18\. Subject has epilepsy. 19. Subject has known severe allergies, e.g., peanut, bee sting, etc. 20. Subject has a known coronary occlusion that cannot be reperfused e.g. known multiple small vessel disease, saphenous vein graft, prior angiography where doctor could not intervene, or jailed occlusion.

Where this trial is running

Glendale, Arizona and 17 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Acute Coronary Syndrome
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.